NovaBridge Biosciences (NBP)

NovaBridge Biosciences is a clinical-stage biopharmaceutical company advancing a focused pipeline of novel biologics targeting gastric cancer and age-related macular degeneration. Headquartered in Rockville, Maryland, the company rebranded from I-Mab in October 2025, signaling a shift toward its international ambitions and a clearer market identity around two cornerstone clinical programs in mid-stage development.

The company operates with a lean structure concentrated on two therapeutic areas: oncology, primarily gastric cancer, and ophthalmology, specifically wet AMD. Both pipelines represent significant unmet medical needs in their respective spaces. Givastomig, its lead oncology asset, is a Claudin 18.2-targeted bispecific antibody that has demonstrated activity in gastric and gastrointestinal malignancies. VIS-101, jointly developed with Visara Therapeutics, is a bispecific VEGF-A and Angiopoietin-2 inhibitor showing promise in wet age-related macular degeneration and related retinal conditions.

Development Stage and Capital Position

NovaBridge operates as a clinical-stage company with no approved products on the market. Both lead programs are in Phase 2 clinical trials, positioning the company in the mid-to-late development window typical of biotech firms before regulatory submission. In early 2026, the company announced a cash position of approximately $210.8 million, reported to fund operations through 2028. This runway provides runway for completion of current clinical studies and, potentially, initiation of pivotal Phase 3 trials, though biotech timelines and spending rates often shift.

Revenue and Commercialization Model

The company currently generates no revenue from product sales. NovaBridge operates on a development-stage model, funding operations through equity financing and, historically, collaboration arrangements. The strategic focus is on advancing clinical evidence and preparing for potential regulatory pathways leading to approval and eventual commercialization. The company has explored partnership opportunities and has indicated interest in accessing capital markets internationally, including a proposed dual listing on Nasdaq and the Hong Kong Stock Exchange.

Competitive Position and Technology

NovaBridge’s approach centers on bispecific antibodies and bifunctional biologics—engineered proteins that simultaneously engage two biological targets. This architecture is intended to provide advantages in efficacy and durability compared to conventional monoclonal antibodies. Givastomig targets Claudin 18.2, a tumor-associated antigen in gastric cancers, while also engaging 4-1BB, a co-stimulatory immune receptor, to amplify anti-tumor immunity. VIS-101 targets the VEGF-A and Angiopoietin-2 axis, a combination intended to address both abnormal vessel growth and loss of vascular stability in wet AMD.

The gastric cancer space has seen growing interest in Claudin 18.2-targeting approaches, with several competitors in development. NovaBridge’s program has shown early tolerability and efficacy signals in Phase 1b studies, though competitive positioning will ultimately depend on comparative clinical data. The wet AMD space, dominated by approved treatments like anti-VEGF monoclonal antibodies, represents a large and mature market; VIS-101’s potential lies in demonstrating superior durability or convenience.

Key Risks

Clinical risk is paramount: advancing from Phase 2 to Phase 3 and ultimately to regulatory approval involves substantial uncertainty. Clinical trials can fail or demonstrate insufficient efficacy relative to existing standards of care, or safety issues can emerge requiring dose reductions or trial halts. Capital requirements remain a central constraint—even with a two-year runway, reaching approval typically requires billions of dollars across a portfolio, and NovaBridge’s relatively modest cash position relative to the scale of late-stage oncology and ophthalmology trials means future financing will be necessary. Competitive pressure from larger pharma and better-capitalized biotech firms with similar mechanisms is real and growing. Regulatory uncertainty in the U.S. and Europe adds execution risk, particularly for novel antibody constructs.

Development Snapshot

How to Evaluate the Company

A reader following NovaBridge should track clinical data releases for both programs—safety, tolerability, and efficacy trends matter more than timeline announcements, which often slip. The company’s quarterly investor communications and 10-K filings detail cash burn and projected runway. For oncology investors, comparative efficacy signals relative to other Claudin 18.2 programs (such as Astellas’ poteligeo or other preclinical competitors) will shape perceived competitive moat. For ophthalmology-focused investors, wet AMD is a crowded market; VIS-101’s advantage must justify its cost and approval pathway. The company’s international regulatory plans—particularly the Hong Kong listing interest—bear watching for capital-raising and market-access implications. Biotech clinical pipelines live or die on trial results; catalysts are usually tied to Phase 2 data presentations and regulatory feedback.